ZHUYONG MEI to Immunotherapy, Adoptive
This is a "connection" page, showing publications ZHUYONG MEI has written about Immunotherapy, Adoptive.
Connection Strength
0.537
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.148
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.101
-
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
Score: 0.094
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.092
-
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43.
Score: 0.066
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.037